USA-based Mylan Laboratories says that its revenue for the third quarter ended December 31, 2005, increased 7% to $311.2 million from $291.0 million in the same period last year. The quarter also saw the firm's earning per diluted share reach $0.25 and Generally-Accepted Accounting Principles earnings of $0.22. The company updated its adjusted diluted earning per share guidance for the year ended March 31, 2006, from $0.94 to $1.00.
Mylan added that products launched after January 1, 2005, contributed $47.9 million to its net revenues during the the final three months of 2005, the majority of which stemmed from the fentanyl transdermal system, the equivalent of Alza's analgesic Duragesic.
In addition, the sale of Apokyn (apomorphine), used in the treatment of hypomobility associated with advanced Parkinson's disease, to Vernalis added $3.6 million to Mylan's revenue. Mylan's stock soared 12%, or $2.28, on the day of the announcement to $21.58, in high volume trading on the New York Stock Exchange. Wachovia Capital Markets analyst Michael Tong upgraded his rating on the company's shares to outperform, adding that the increased stability in Mylan's core business has cut its costs and increased its expansion potential.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze